0001246360-15-001488.txt : 20150313 0001246360-15-001488.hdr.sgml : 20150313 20150313174908 ACCESSION NUMBER: 0001246360-15-001488 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150311 FILED AS OF DATE: 20150313 DATE AS OF CHANGE: 20150313 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SYNAGEVA BIOPHARMA CORP CENTRAL INDEX KEY: 0000911326 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 561808663 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 33 HAYDEN AVE. CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: (781) 357-9900 MAIL ADDRESS: STREET 1: 33 HAYDEN AVE. CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: TRIMERIS INC DATE OF NAME CHANGE: 19970516 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Heberlig Chris CENTRAL INDEX KEY: 0001532217 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23155 FILM NUMBER: 15700525 MAIL ADDRESS: STREET 1: 128 SPRING STREET, SUITE 520 CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 form.xml PRIMARY DOCUMENT X0306 4 2015-03-11 false 0000911326 SYNAGEVA BIOPHARMA CORP GEVA 0001532217 Heberlig Chris 33 HAYDEN AVE LEXINGTON MA 02421 false true false false SVP, Finance and Business Ops. Common Stock 2015-03-11 4 A false 86 76.88 A 390 D Common Stock 2015-03-11 4 M false 7500 40.74 A 7890 D Common Stock 2015-03-11 4 S false 900 100.44 D 6990 D Common Stock 2015-03-11 4 S false 600 101.38 D 6390 D Common Stock 2015-03-11 4 S false 900 102.46 D 5490 D Common Stock 2015-03-11 4 S false 3290 103.55 D 2200 D Common Stock 2015-03-11 4 S false 1510 104.57 D 690 D Common Stock 2015-03-11 4 S false 300 105.74 D 390 D Stock Option (Right to Buy) 40.74 2015-03-11 4 M false 7500 0 D 2022-06-27 Common Stock 7500 7500 D The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Synageva BioPharma Corp. Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2014 through December 31, 2014. This transaction is also exempt under Rule 16b-3(c). The reporting person is voluntarily reporting this transaction as of 03/11/2015, but the actual transaction took place on 12/31/2014, the last trading day of the option period under the ESPP. In accordance with the ESPP, these shares were purchased based on 85% of the closing stock price on July 1, 2014, the first trading day of the option period. The stock option exercise and sale of shares of the Company's common stock (the "Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 3, 2014. The Stock Option granted the reporting person an option to purchase 15,000 Shares. 25% of such Shares vested and became exercisable on 06/27/2013, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $100.10 to $100.95. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $101.12 to $101.88. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $101.98 to $102.94. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $103.00 to $103.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $104.15 to $105.00. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $105.59 to $106.01. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. /s/ Chris Heberlig 2015-03-13